Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant.
Ito S, Hirobe S, Kawakita T, Saito M, Quan YS, Kamiyama F, Ishii KJ, Nagao M, Fujisawa T, Tachibana M, Okada N.
Ito S, et al. Among authors: tachibana m.
Pharmaceutics. 2020 Mar 15;12(3):267. doi: 10.3390/pharmaceutics12030267.
Pharmaceutics. 2020.
PMID: 32183437
Free PMC article.